Omeicos Therapeutics GmbH
- Biotech or pharma, therapeutic R&D
OMEICOS is a clinical stage company and develops first-in-class, small molecules.
Lead asset OMT-28 exerts strong anti-inflammatory activity with improvement of mitochondrial function and significantly reduces fibrosis across pre-clinical models.
OMT-28 is in Phase 2a clinical development for primary mitochondrial disease but multiple applications in cardio/renal, metabolism/inflammation and vascular/eye are accessible due to its unique Mode of Action.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}